[Notice] Updates on Case Study Outcomes and Track Record Summary

RevolKa Reimagines Antibody Engineering with “RevoAb®”

RevolKa Director & CSO Prof. Mitsuo Umetsu (Tohoku-Univ.) and Team Announce New AI-Driven Method toAccelerate Discovery of Highly Functional Antibodies

Corporate Website Renewal Notice